Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View.
Molecular neurobiology June 4, 2025 Naser-Aldin Lashgari, Mahla Khalaji, Pouria Rana et al. 7 citations
Psychedelic compounds such as LSD, psilocybin, MDMA, DMT, and ketamine show therapeutic potential for neurological and psychiatric disorders including depression, PTSD, Alzheimer's disease, and Parkinson's disease. Their benefits arise from multiple mechanisms: anti-inflammatory effects (reducing cytokines like IL-6 and TNF-α), antioxidant activity (inducing SOD), and enhancing neuroplasticity via increased BDNF expression. They also modulate serotonin and dopamine systems. Compared to conventional treatments, psychedelics offer faster onset, longer-lasting effects, and possible disease-modifying properties, making them promising candidates for future therapies.